Clinical Trials
6 trialsNCT04902443 2026-06-05
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT01412515 2026-06-04
A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma
Institut National de la Santé Et de la Recherche Médicale, France
Phase 2 Terminated
NCT02659930 2026-06-04
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT05907759 2026-06-02
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04303117 2026-06-01
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT04514484 2026-05-28
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting